Global Immuno-oncology Treatment Devices and Drugs Market Size, Forecast, and Trend Highlights Over 2025-2037
Immuno-oncology Treatment Devices and Drugs Market size was valued at USD 98.9 billion in 2024 and is projected to reach USD 380.6 billion by the end of 2037, rising at a CAGR of 13.2% during the forecast period, i.e., 2025-2037. In 2025, the industry size of immuno-oncology treatment devices and drugs is evaluated at USD 111.5 billion.
The global market is witnessing significant growth driven by the increasing cancer burden and the growing demand for immuno-diagnostic devices. In this regard, the World Health Organization’s 2024 report projects more than 29 million annual cancer cases by 2030, which is a 19.4 million upsurge from 2020. This has created an appreciable necessity for CAR-T therapies and checkpoint inhibitors. Besides, NCI in 2024 notes that 62% of late-stage cancers are currently eligible for immunotherapy, which marks a 42% up from 2015, reflecting the heightened adoption. To meet this, the APIs for these drugs are being drawn from the U.S., Germany, and China.
The current dynamics in the immuno-oncology treatment devices and drugs market are further carried out by research initiatives and trade activities. In this regard, NIH in 2024 assigned USD 26 billion towards immune oncology, out of which 66% was allocated towards clinical trials. Meanwhile Cancer Moonshot Initiative allocated USD 2.6 billion, aiming to accelerate immunotherapy adoption. WTO in 2024 states that the U.S. and EU are critical exporters of finished therapeutics, meanwhile China and India are leading the market with API production accounting for 45% of exports across the world. This wider market scope readily allows businesses in this sector.
